Plain-English translation of NCT07062198 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing CMA2, a combination supplement made up of four nutrients (NAC, LCAT, niacinamide, and L-serine), to see if it can help improve how the brain works and support daily functioning in people with Alzheimer's disease. About 845 people will participate across nine clinics in Turkey. Half will receive the medication twice daily, and half will receive a placebo (a pill with no active ingredients) so researchers can compare how well the treatment actually works.
Current Alzheimer's treatments have limited effectiveness, and researchers believe that supporting the brain's metabolic health—the way brain cells produce and use energy—might help slow cognitive decline. This medication is designed to provide nutrients that may boost brain metabolism and protect thinking abilities.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic four times over six months: an initial screening visit, a start visit where you receive your first dose and are monitored for two hours, a check-in at week 13, and a final visit at week 26. You'll take your assigned pill twice a day at home, and the clinic will call you monthly to check on how you're doing and whether you're having any side effects. Blood samples will be collected to measure changes in your brain chemistry, and some patients may optionally provide additional samples including spinal fluid, saliva, and stool samples for deeper analysis.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Turkey (Türkiye)